Pulsed light therapy in refractory dry eye disease associated with Meibomian gland dysfunction: Effectiveness in symptomatic response
Archivos de la Sociedad Española de Oftalmología (English Edition) · 2025
DOI: 10.1016/j.oftale.2025.01.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archivos de la Sociedad Española de Oftalmología (English Edition), 2025. Verfasst von S Turizo Mejía und 6 weiteren Autor:innen. Beteiligte Einrichtung: Residente de Oftalmología, Universidad CES, Medellín, Colombia. Electronic address: saraturizo@gmail.com. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Meibomian Gland Dysfunction, Intense Pulsed Light Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To determine the effectiveness of intense pulsed light (IPL) therapy in improving symptoms in patients with a diagnosis of evaporative dry eye disease secondary to Meibomian gland dysfunction (MGD) refractory to conventional treatment. METHODS: Pseudo-experimental, analytical, prospective, longitudinal, interventional study. Patients aged 18-74 years with a diagnosis of dry eye disease refractory to conventional dry eye treatment with the presence of DGM were included. A total of 4 IPL sessions were performed at days 0, 15, 45 and 75. At each visit, ocular surface disease index (OSDI) data and 1-10 analog scale were taken as objective evidence of symptomatic status. RESULTS: Sixty three patients were included, median age was 43 years, 61.5% were female, 42.9% of patients used one conventional treatment for dry eye prior to IPL therapy and 57.1% of patients used two or more treatments. Sixty three patients completed at least one IPL session, 45 had two sessions, 32 had three sessions and 18 had four sessions. After the fourth session symptomatic improvement was 50.8% based on the OSDI scale, and 71.4% based on the analogous symptom scale. CONCLUSION: This study demonstrates that IPL therapy is effective in symptomatic improvement in patients with MGD diagnosis refractory to conventional treatment, showing that after four sessions in at least 50% of patients both with the OSDI measurement and with the ocular surface symptomatology analog scale.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Residente de Oftalmología, Universidad CES, Medellín, Colombia. Electronic address: saraturizo@gmail.com.
- Residente de Oftalmología, Universidad CES, Medellín, Colombia.
- Oftalmólogo, Epidemólogo, Magíster en educación médica, subespecialista en segmento anterior, Clínica CES, Medellín, Colombia.
- Oftalmóloga, subespecialista en córnea, Clínica Clofán, Medellín, Colombia.
- Oftalmólogo, subespecialista en córnea y enfermedades externas, jefe servicios de Córnea de la Universidad CES, Medellín, Colombia.
Zitieren
APA
Turizo Mejía, S., Jaramillo, L. M., Gil Muñoz, J. C., Buitrago Salazar, J. C., Rodríguez Gómez, A. M., Mejía Echavarría, L. F., & Escobar Giraldo, M. (2025). Pulsed light therapy in refractory dry eye disease associated with Meibomian gland dysfunction: Effectiveness in symptomatic response. Archivos de la Sociedad Española de Oftalmología (English Edition). https://doi.org/10.1016/j.oftale.2025.01.002
Vancouver
Turizo Mejía S, Jaramillo LM, Gil Muñoz JC, Buitrago Salazar JC, Rodríguez Gómez AM, Mejía Echavarría LF, et al. Pulsed light therapy in refractory dry eye disease associated with Meibomian gland dysfunction: Effectiveness in symptomatic response. Archivos de la Sociedad Española de Oftalmología (English Edition). 2025. doi:10.1016/j.oftale.2025.01.002
BibTeX
@article{TurizoMeja2025,
author = {Turizo Mejía, S and Jaramillo, L M and Gil Muñoz, J C and Buitrago Salazar, J C and Rodríguez Gómez, A M and Mejía Echavarría, L F and Escobar Giraldo, M},
title = {Pulsed light therapy in refractory dry eye disease associated with Meibomian gland dysfunction: Effectiveness in symptomatic response},
journal = {Archivos de la Sociedad Española de Oftalmología (English Edition)},
year = {2025},
doi = {10.1016/j.oftale.2025.01.002}
}
EUVIMED